Biocon Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "S&P Global Upgrades Biocon Biologics Credit Rating To BB+ Revises Outlook to Stable ".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited informed the stock exchange about a press release dated January 28, 2026, stating that S&P Global has upgraded the credit rating of its subsidiary Biocon Biologics to BB+. Along with the rating upgrade, S&P has also revised the outlook on Biocon Biologics to Stable. While BB+ still falls in the speculative (non-investment) grade category, it represents a positive improvement in the subsidiary's creditworthiness. The upgrade reflects improved financial metrics and reduced perceived default risk for Biocon Biologics.
This is a positive development for Biocon shareholders, signaling improved financial health and operational stability at its key subsidiary, Biocon Biologics. A stable outlook and higher rating may help the company secure debt at better terms in the future, reducing finance costs.